OMERS ADMINISTRATION Corp Grows Stock Holdings in West Pharmaceutical Services, Inc. $WST

OMERS ADMINISTRATION Corp grew its position in West Pharmaceutical Services, Inc. (NYSE:WST) by 23.6% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 12,769 shares of the medical instruments supplier’s stock after buying an additional 2,442 shares during the quarter. OMERS ADMINISTRATION Corp’s holdings in West Pharmaceutical Services were worth $3,200,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently bought and sold shares of the company. Norges Bank purchased a new position in West Pharmaceutical Services during the 4th quarter valued at about $272,041,000. Generation Investment Management LLP grew its position in West Pharmaceutical Services by 60.0% in the 4th quarter. Generation Investment Management LLP now owns 1,561,869 shares of the medical instruments supplier’s stock valued at $429,733,000 after acquiring an additional 585,855 shares in the last quarter. T. Rowe Price Investment Management Inc. increased its stake in West Pharmaceutical Services by 67.5% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 1,174,962 shares of the medical instruments supplier’s stock worth $323,280,000 after purchasing an additional 473,547 shares during the period. Steadfast Capital Management LP purchased a new stake in West Pharmaceutical Services during the third quarter worth about $123,667,000. Finally, AQR Capital Management LLC lifted its position in shares of West Pharmaceutical Services by 420.1% during the third quarter. AQR Capital Management LLC now owns 545,879 shares of the medical instruments supplier’s stock worth $142,949,000 after purchasing an additional 440,929 shares in the last quarter. Institutional investors and hedge funds own 93.90% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on WST. Barclays upgraded shares of West Pharmaceutical Services from an “equal weight” rating to an “overweight” rating and lifted their price objective for the company from $310.00 to $400.00 in a report on Tuesday, June 9th. BNP Paribas Exane assumed coverage on shares of West Pharmaceutical Services in a research report on Monday, July 13th. They issued an “outperform” rating and a $447.00 price target for the company. Wolfe Research started coverage on shares of West Pharmaceutical Services in a research note on Monday, June 1st. They issued an “outperform” rating and a $375.00 price target for the company. Zacks Research raised West Pharmaceutical Services from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, May 13th. Finally, Stephens reiterated an “overweight” rating and issued a $360.00 price objective on shares of West Pharmaceutical Services in a research note on Tuesday, June 2nd. Two analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $364.42.

West Pharmaceutical Services Stock Up 1.0%

Shares of NYSE:WST opened at $331.52 on Tuesday. West Pharmaceutical Services, Inc. has a fifty-two week low of $223.83 and a fifty-two week high of $386.00. The firm’s 50 day moving average price is $337.57 and its 200 day moving average price is $287.85. The company has a quick ratio of 2.12, a current ratio of 2.82 and a debt-to-equity ratio of 0.07. The stock has a market cap of $23.33 billion, a price-to-earnings ratio of 42.45, a price-to-earnings-growth ratio of 2.56 and a beta of 1.16.

West Pharmaceutical Services (NYSE:WST) last posted its quarterly earnings results on Thursday, July 23rd. The medical instruments supplier reported $2.37 EPS for the quarter, topping the consensus estimate of $2.08 by $0.29. West Pharmaceutical Services had a net margin of 16.98% and a return on equity of 20.11%. The company had revenue of $872.30 million during the quarter, compared to analysts’ expectations of $839.98 million. During the same quarter in the previous year, the business posted $1.84 EPS. The firm’s revenue was up 13.8% on a year-over-year basis. West Pharmaceutical Services has set its Q3 2026 guidance at 2.140-2.240 EPS and its FY 2026 guidance at 8.850-9.050 EPS. As a group, equities research analysts predict that West Pharmaceutical Services, Inc. will post 8.93 earnings per share for the current fiscal year.

West Pharmaceutical Services Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, August 5th. Investors of record on Wednesday, July 29th will be issued a $0.22 dividend. This represents a $0.88 annualized dividend and a yield of 0.3%. The ex-dividend date of this dividend is Wednesday, July 29th. West Pharmaceutical Services’s dividend payout ratio is 11.27%.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.